Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 2, 1997, Pages 109-117

  Piazolo, Lukas ^a   Harenberg, Job ^a   Malsch, Reinhard ^a   Hüttner, Franz G ^a   Heene, Dieter L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Certoparin; Dalteparin; LMM heparin; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CERTOPARIN; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030909292     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996078     Document Type: Article

References (37)

1. Hirsh J, MN Levine: Low molecular weight heparin. Blood 1:1-17, 1992.
2. Harenberg J, DL Heene: Pharmacology and special clinical applications of low molecular weight heparin. Am J Hematol 29: 233-240, 1988.
3. Leiorovicz A, H Decousus. JL Bosson: Prevention of venous thromboemholic events: A prospective survey in surgical patients. Thromb Haemostas 73:1095 (Abstr), 1995.
4. Malsch R, M Guerrini, G Torri, G Löhr, B Casu, J Harenberg: Synthesis of a N'alkylamine anticoagulant active low molecular mass (LMM) heparin for radioactive and fluorescent labeling. Anal Biochem 217:255-264, 1994.
5. Nielsen JL, P Østergaard: Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 543:52-56, 1988.
6. Caranobe C, M Petitou, D Dupouy, AM Gabaig, P Sié, MR Buchanan. B Boneu: Heparin fractions with high and low affinities to antithrombin III are cleared at different rates. Thromb Res 43:635-641, 1986.
7. Barrowcliffe TW, AD Curtis, EA Johnsen, DP Thomas: An international standard for low molecular weight heparin. Thromb Haemostas 60:1-71, 1988.
8. Aiach M, A Michaud, JL Balian, M Lefebvre, M Woler, J Fourtillian: A new low molecular weight heparin. Thromb Res 31: 611-621, 1983.
9. Fareed J, JM Walenga, D Hoppensteadt. X Huan, A Racanelli: Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 18:3-15, 1988.
10. Collignon F, A Frydom, H Caplain, ML Ozoux, Y Le Roux, J Bouthier, JJ Thébault: Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemostas 73:630-640, 1996.
11. Teien AN, M Lie, U Abildgaard: Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 8:413-416, 1976.
12. Visser A, DG Meuleman: Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans. Thromb Res 58:469-479, 1990.
13. Dautzenberg MD, L Bara, P Cornu. M Samama: Specific anti-Xa activity of LMWH (Kabi 2165, CY 216, PK 10169) against the first international standard of LMWH: A collaborative study. Thromb Haemostas 64:490-491, 1990.
14. Harenberg J: Modified anti-factor Xa chromogenic substrate assay for heparin and low molecular weight heparins. Arztl Lab 33:39-41, 1987.
15. Harenberg J, C Giese, A Knödler, R Zimmermann: Comparative study of a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 19:13-20, 1989.
16. Horten D, KD Philips: The nitrous acid deamination of glycosides and acetates of 2-amino-2-desoxy-D-glucose. Carbohydr Res 30: 367-374, 1973.
17. Harenberg J, JX de Vries: Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 261:287-292, 1983.
18. Harenberg J. R Malsch: N-Alkylamin und N-Arylalkylamin-derivate von Heparin: Verfahren zu ihrer Herstellung und ihre Verwendung. German Patent No. P 4217916.5, 1993.
19. Goodfriend TL, L Levine, GD Fasman: Antibodies to bradykinin and angiotensin: A use of carbodiimides in immunology. Science 144:1344-1346, 1964.
20. Piazolo L, J Harenberg, R Malsch, DL Heene: Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes. Semin Thromb Hemostas 20: 227-235, 1994.
21. Pedersen PC, PB Østergaard, U Hedner, D Bergqvist, T Mätzsch: Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 61:477-487, 1991.
22. Fareed J, JM Walenga, M Lassen, L Borris, D Hoppensteadt, R Murphy, A Ahsan, S Weber, LN Jorgensen, O Hauch, P Willie-Jorgensen. R Pifarre: Pharmacologic profile of a low molecular weight heparin (enoxaparin): Experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand Suppl 556:75:90, 1990.
23. 99mTc-labelled enoxaparin in rat: Evaluation of dosimetry parameters. Biomed Pharmacother 44:317-323, 1990.
24. Saivin S, M Petitou, JC Lormeau, D Dupouy, P Sie, C Caranobe, G Houin, B Boneu: Pharmacological properites of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects. Thromb Haemostas 67:346-351, 1992.
25. Barrowcliffe TW, AD Curtis, TP Tomlinson, AR Hubbard, EA Lohnson, DP Thomas: Standardization of low molecular weight heparins: A collaborative study. Thromb Haemostas 54:675-679. 1985.
26. Dawes J: Comparison of the pharmacokinetics of enoxaparin (Clexane®) and unfractionated heparin. Acta Chir Scand Suppl 556:68-74, 1990.
27. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40:498-530, 1990.
28. Boneu B, C Caranobe, S Salvin, F Dol, P Sié: Pharmacokinetics of heparin and of dermatan sulfate: Clinical implications. Adv Exp Med Biol 313:231-247, 1992.
29. Hemker HC, S Wielders, H Kessls, S Béguin: Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemostas 70:617-624, 1993.
30. Béguin S, S Wielders, JC Lormeau, HC Hemker: The mode of action of CY 216 and CY 222 in plasma. Thromb Haemostas 67: 33-41, 1992.
31. Bendetowicz AV, S Béguin, H Caplain, HC Hemker: Pharmacokinetics and pharmacodynamics of low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin. A three way cross study in healthy volunteers. Thromb Haemostas 71:305-313, 1994.
32. Bendetowicz AV, E Pacaud, S Béguin, A Uzan, HC Hemker: On the relationship between molecular mass and anticoagulant activity of a low molecular weight heparin (enoxaparin). Thromb Haemostas 67:556-562, 1992.
33. Bratt G, E Törnbohm, D Locker, K Bergström: A human pharmacological study comparing conventional heparin and low molecular weight fragment. Thromb Haemostas 53:206-211, 1985.
34. Bratt G, E Törnbohm, L Widlund, D Locker: Low molecular weight heparins (Kabi 2165. Fragmin®): Pharmacokinetics after intravenous and subcutaneous administration. Thromb Res 42: 612-620, 1986.
35. Bara L, M Samama: Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 543:65-72, 1988.
36. Bara L, M Samama: Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 556:57-61, 1990.
37. Bergonzini GL, P Bianchini, G Mascellani, B Osima, B Parma, N Volpi: Different pharmacokinetics, antithrombotic activity and bleeding effects of heparin and two new fragments administered in rat by subcutaneous route. Arzneim Forsch 42:1322-1328, 1992.